Celyad Presents Update on CYAD-01 Hematological Malignancies Clinical Program at 60th ASH Annual Meeting

Celyad Presents Update on CYAD-01 Hematological Malignancies Clinical Program at 60th ASH Annual Meeting

Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-based CAR-T Therapy, CYAD-01, in Acute Myeloid Leukemia

Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-based CAR-T Therapy, CYAD-01, in Acute Myeloid Leukemia

Celyad Doses First mCRC Patient in the Phase 1 alloSHRINK Trial Evaluating Non-Gene Edited Allogeneic CAR-T Candidate, CYAD-101

Celyad Doses First mCRC Patient in the Phase 1 alloSHRINK Trial Evaluating Non-Gene Edited Allogeneic CAR-T Candidate, CYAD-101

Celyad Announces Third Quarter 2018 Business Update

Celyad Announces Third Quarter 2018 Business Update

Celyad to Participate at Upcoming Healthcare Conferences

Celyad to Participate at Upcoming Healthcare Conferences

Differential effects of target ligands upon NKG2D CAR T cell activation

Differential effects of target ligands upon NKG2D CAR T cell activation

Generating Allogeneic CAR T cells without Gene Editing

Generating Allogeneic CAR T cells without Gene Editing

Endogenous DAP10 provides optimal co‐stimulation for NKG2D‐based CARs

Endogenous DAP10 provides optimal co‐stimulation for NKG2D‐based CARs

Functional screening of different anti-B7H6 CAR designs

Functional screening of different anti-B7H6 CAR designs

Overcoming target‐driven fratricide for CAR‐T cell therapy

Overcoming target‐driven fratricide for CAR‐T cell therapy

Celyad Presents Update on CYAD-01 Solid Tumor Clinical Program at the SITC 33rd Annual Meeting

Celyad Presents Update on CYAD-01 Solid Tumor Clinical Program at the SITC 33rd Annual Meeting

The co-expression of a single shRNA targeting MICA and MICB with a NKG2D CAR generates CAR-T cells resistant to target driven fratricide and improves CAR T cell persistence in vivo

The co-expression of a single shRNA targeting MICA and MICB with a NKG2D CAR generates CAR-T cells resistant to target driven fratricide and improves CAR T cell persistence in vivo